VistaGen Therapeutics, Inc. (VTGN) Financials
VTGN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 131.1 million | 7.8 million |
| 2023-09-30 | 42.2 million | 6.6 million |
| 2023-06-30 | 15.0 million | 8.2 million |
| 2023-03-31 | 21.1 million | 9.0 million |
VTGN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -4.6 million | 506700 |
| 2023-09-30 | -6.2 million | 583700 |
| 2023-06-30 | -7.9 million | 569100 |
| 2023-03-31 | -7.3 million | 601500 |
VTGN Net Income
No data available :(
VTGN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 126.6 million | - | 2.3 million |
| 2023-09-30 | 37.6 million | - | 2.4 million |
| 2023-06-30 | 9.6 million | - | 2.5 million |
| 2023-03-31 | 16.6 million | - | 2.6 million |
VTGN Shares Outstanding
VTGN Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 32300 | 4.5 million | 3.8 million | 143400 |
| 2023-09-30 | - | 3.9 million | 3.2 million | 140000 |
| 2023-06-30 | - | 4.2 million | 2.9 million | 84000 |
| 2023-03-31 | 212000 | 9.3 million | 3.1 million | 84000 |
VTGN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 411400 | 143200 |
| 2023-09-30 | 277700 | 140300 |
| 2023-06-30 | 177600 | 340000 |
| 2023-03-31 | 175600 | 153600 |
VTGN
Price: $4.50
52 week price:
Earnings Per Share: -2.96 USD
P/E Ratio: -1.05
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 11.3 million
Ebitda: -2.8 millionMarket Capitalization: 136.2 million